Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Impact of a Chronic Total Occlusion on Outcomes After FFR-Guided PCI or Coronary Bypass Surgery: A FAME 3 Substudy

H. Otsuki, K. Takahashi, FM. Zimmermann, K. Mavromatis, A. Aminian, N. Jagic, JE. Dambrink, P. Kala, P. MacCarthy, N. Witt, Y. Kobayashi, T. Takahashi, YJ. Woo, AC. Yeung, B. De Bruyne, NHJ. Pijls, WF. Fearon, FAME 3 Trial Investigators

. 2024 ; 17 (11) : e014300. [pub] 20241106

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, multicentrická studie, srovnávací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003563

BACKGROUND: The clinical impact of a chronic total occlusion (CTO) in patients with 3-vessel coronary artery disease undergoing fractional flow reserve-guided percutaneous coronary intervention (PCI) with current-generation drug-eluting stents or coronary artery bypass grafting (CABG) is unclear. METHODS: The FAME 3 trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation 3) compared fractional flow reserve-guided PCI with CABG in patients with 3-vessel coronary artery disease. The primary end point was major adverse cardiac and cerebrovascular events, a composite of death, myocardial infarction, stroke, or repeat revascularization at 1 year. In this substudy, the 3-year outcomes were analyzed in patients with or without a CTO. RESULTS: Of the patients randomized to PCI or CABG in the FAME 3 trial, 305 (21%) had a CTO. In the PCI arm, revascularization of the CTO was attempted in 61% with a procedural success rate of 88%. The incidence of major adverse cardiac and cerebrovascular events at 3 years was not significantly different between those with or without a CTO in both the PCI (15.2% versus 20.1%; adjusted hazard ratio, 0.62 [95% CI, 0.38-1.03]; P=0.07) and the CABG (13.0% versus 12.9%; adjusted hazard ratio, 0.96 [95% CI, 0.55-1.66]; P=0.88) arms. In those without a CTO, PCI was associated with a significantly higher risk of major adverse cardiac and cerebrovascular events compared with CABG (adjusted hazard ratio, 1.61 [95% CI, 1.20-2.17]; P<0.01) but not in those with a CTO (adjusted hazard ratio, 1.21 [95% CI, 0.64-2.28]; P=0.56; Pinteraction=0.31). CONCLUSIONS: The presence of a CTO did not significantly impact the treatment effect of PCI versus CABG at 3 years in patients with 3-vessel coronary artery disease. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02100722.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003563
003      
CZ-PrNML
005      
20250206104420.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1161/CIRCINTERVENTIONS.124.014300 $2 doi
035    __
$a (PubMed)39502029
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Otsuki, Hisao $u Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University, CA (H.O., K.T., A.C.Y., W.F.F.)
245    10
$a Impact of a Chronic Total Occlusion on Outcomes After FFR-Guided PCI or Coronary Bypass Surgery: A FAME 3 Substudy / $c H. Otsuki, K. Takahashi, FM. Zimmermann, K. Mavromatis, A. Aminian, N. Jagic, JE. Dambrink, P. Kala, P. MacCarthy, N. Witt, Y. Kobayashi, T. Takahashi, YJ. Woo, AC. Yeung, B. De Bruyne, NHJ. Pijls, WF. Fearon, FAME 3 Trial Investigators
520    9_
$a BACKGROUND: The clinical impact of a chronic total occlusion (CTO) in patients with 3-vessel coronary artery disease undergoing fractional flow reserve-guided percutaneous coronary intervention (PCI) with current-generation drug-eluting stents or coronary artery bypass grafting (CABG) is unclear. METHODS: The FAME 3 trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation 3) compared fractional flow reserve-guided PCI with CABG in patients with 3-vessel coronary artery disease. The primary end point was major adverse cardiac and cerebrovascular events, a composite of death, myocardial infarction, stroke, or repeat revascularization at 1 year. In this substudy, the 3-year outcomes were analyzed in patients with or without a CTO. RESULTS: Of the patients randomized to PCI or CABG in the FAME 3 trial, 305 (21%) had a CTO. In the PCI arm, revascularization of the CTO was attempted in 61% with a procedural success rate of 88%. The incidence of major adverse cardiac and cerebrovascular events at 3 years was not significantly different between those with or without a CTO in both the PCI (15.2% versus 20.1%; adjusted hazard ratio, 0.62 [95% CI, 0.38-1.03]; P=0.07) and the CABG (13.0% versus 12.9%; adjusted hazard ratio, 0.96 [95% CI, 0.55-1.66]; P=0.88) arms. In those without a CTO, PCI was associated with a significantly higher risk of major adverse cardiac and cerebrovascular events compared with CABG (adjusted hazard ratio, 1.61 [95% CI, 1.20-2.17]; P<0.01) but not in those with a CTO (adjusted hazard ratio, 1.21 [95% CI, 0.64-2.28]; P=0.56; Pinteraction=0.31). CONCLUSIONS: The presence of a CTO did not significantly impact the treatment effect of PCI versus CABG at 3 years in patients with 3-vessel coronary artery disease. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02100722.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a koronární bypass $x škodlivé účinky $x mortalita $7 D001026
650    12
$a koronární angioplastika $x škodlivé účinky $x mortalita $7 D062645
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    12
$a koronární okluze $x diagnostické zobrazování $x mortalita $x terapie $x patofyziologie $7 D054059
650    _2
$a lidé středního věku $7 D008875
650    _2
$a výsledek terapie $7 D016896
650    _2
$a chronická nemoc $7 D002908
650    12
$a frakční průtoková rezerva myokardu $7 D053805
650    _2
$a rizikové faktory $7 D012307
650    12
$a stenty uvolňující léky $7 D054855
650    _2
$a časové faktory $7 D013997
650    12
$a koronární angiografie $7 D017023
650    _2
$a nemoci koronárních tepen $x terapie $x mortalita $x diagnostické zobrazování $x patofyziologie $7 D003324
650    _2
$a prediktivní hodnota testů $7 D011237
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Takahashi, Kuniaki $u Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University, CA (H.O., K.T., A.C.Y., W.F.F.)
700    1_
$a Zimmermann, Frederik M $u Catharina Hospital, Eindhoven, the Netherlands (F.M.Z., N.H.J.P.) $u St. Antonius Hospital, Nieuwegein, the Netherlands. (F.M.Z.)
700    1_
$a Mavromatis, Kreton $u Atlanta VA Healthcare System, Decatur, GA (K.M.) $u Emory University School of Medicine, Atlanta, GA (K.M.) $1 https://orcid.org/0000000172501662
700    1_
$a Aminian, Adel $u Centre Hospitalier Universitaire de Charleroi, Belgium (A.A.) $1 https://orcid.org/0000000246679181
700    1_
$a Jagic, Nikola $u Clinical Hospital Centre Zemun, University of Belgrade, Serbia (N.J.)
700    1_
$a Dambrink, Jan-Henk E $u Isala Hospital, Zwolle, the Netherlands (J.-H.E.D.)
700    1_
$a Kala, Petr $u University Hospital Brno and Masaryk University Brno, Bruno, Czech Republic (P.K.) $1 https://orcid.org/0000000244169065
700    1_
$a MacCarthy, Philip $u King's College Hospital, London, United Kingdom (P.M.)
700    1_
$a Witt, Nils $u Karolinska Institute, Department of Clinical Science and Education, Division of Cardiology at Södersjukhuset, Stockholm, Sweden (N.W.) $1 https://orcid.org/0000000195325606
700    1_
$a Kobayashi, Yuhei $u New York-Presbyterian Brooklyn Methodist Hospital, Weill Cornell Medical College, Brooklyn (Y.K.) $1 https://orcid.org/000000016058232X
700    1_
$a Takahashi, Tatsunori $u Cedars-Sinai Medical Center, Los Angeles, CA (T.T.) $1 https://orcid.org/0000000204234715
700    1_
$a Woo, Y Joseph $u Department of Cardiothoracic Surgery and Stanford Cardiovascular Institute, Stanford University, CA (Y.J.W.) $1 https://orcid.org/000000022506492X
700    1_
$a Yeung, Alan C $u Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University, CA (H.O., K.T., A.C.Y., W.F.F.)
700    1_
$a De Bruyne, Bernard $u Cardiovascular Center Aalst, Belgium (B.D.B.) $1 https://orcid.org/000000016567168X
700    1_
$a Pijls, Nico H J $u Catharina Hospital, Eindhoven, the Netherlands (F.M.Z., N.H.J.P.) $1 https://orcid.org/0000000158636966
700    1_
$a Fearon, William F $u Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University, CA (H.O., K.T., A.C.Y., W.F.F.) $u VA Palo Alto Health Care System, CA (W.F.F.) $1 https://orcid.org/0000000317991368
710    2_
$a FAME 3 Trial Investigators
773    0_
$w MED00161049 $t Circulation. Cardiovascular interventions $x 1941-7632 $g Roč. 17, č. 11 (2024), s. e014300
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39502029 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104415 $b ABA008
999    __
$a ok $b bmc $g 2263361 $s 1239570
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 17 $c 11 $d e014300 $e 20241106 $i 1941-7632 $m Circulation. Cardiovascular interventions $n Circ Cardiovasc Interv $x MED00161049
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace